SSKN · As filed with the SEC

STRATA Skin Sciences income statement, by quarter

The statement as STRATA Skin Sciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Consolidated Statements of Operations · USD thousands, except per-share amounts

USD thousands, except per-share amounts	Q4 2025^† 3 months ended Dec 31, 2025	Q3 2025 3 months ended Sep 30, 2025	Q2 2025 3 months ended Jun 30, 2025	Q1 2025 3 months ended Mar 31, 2025	Q4 2024^† 3 months ended Dec 31, 2024
Revenues, net	9,292^†	6,929	7,663	6,812	9,576^†
Cost of revenues	3,678^†	2,745	3,357	3,165	3,954^†
Gross profit	5,614^†	4,184	4,306	3,647	5,622^†
Operating expenses:
Engineering and product development	67^†	172	86	96	200^†
Selling and marketing	3,254^†	3,201	3,533	2,993	3,074^†
General and administrative	2,256^†	2,668	2,911	2,573	2,772^†
Settlement gains	—	(684)	—	—	—
Total operating expenses	5,126^†	5,357	6,530	5,662	9,907^†
Loss from operations	488^†	(1,173)	(2,224)	(2,015)	(4,285)^†
Interest expense	(484)^†	(498)	(491)	(486)	(515)^†
Interest income	66^†	49	226	69	75^†
Other income	0^†	0	0	—	0^†
Other (expense), income net	(418)^†	(449)	(265)	(417)	(440)^†
Net loss	58^†	(1,622)	(2,489)	(2,432)	(4,555)^†
Net loss per share of common stock - basic (in Dollars per share)	—	(0.36)	(0.60)	(0.58)	—
Net loss per share of common stock - diluted (in Dollars per share)	—	(0.36)	(0.60)	(0.58)	—
Weighted average shares of common stock outstanding - basic (in Shares)	—	4,481,337	4,171,161	4,171,161	—
Weighted average shares of common stock outstanding - diluted (in Shares)	—	4,481,337	4,171,161	4,171,161	—

† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.